| Cell line name |
OV-MZ-5 |
|---|
| Accession |
CVCL_X954 |
|---|
| Resource Identification Initiative |
To cite this cell line use: OV-MZ-5 (RRID:CVCL_X954) |
|---|
| Comments |
Doubling time: 40 hours (PubMed=1500230).
Derived from site: Metastatic; Ascites; UBERON=UBERON_0007795. |
|---|
| Sequence variations |
|
|---|
| Disease |
Ovarian serous cystadenocarcinoma (NCIt: C7978) |
|---|
| Species of origin |
Homo sapiens (Human)
(NCBI Taxonomy: 9606) |
|---|
| Sex of cell |
Female |
|---|
| Age at sampling |
57Y |
|---|
| Category |
Cancer cell line |
|---|
| Publications | PubMed=1500230; DOI=10.1002/ijc.2910520115
Volker J. Mobus, Claus-Dieter Gerharz, U. Press, Roland Moll, Timothy Beck, Walter Mellin, Kunhard Pollow, Paul-Georg Knapstein, Rolf Kreienberg;
Morphological, immunohistochemical and biochemical characterization of 6 newly established human ovarian carcinoma cell lines.
Int. J. Cancer 52:76-84(1992) PubMed=11242531; DOI=10.1089/10430340150504019
Ansgar Bruning, Tanja Kohler, Sven Roy Quist, Shan Wang-Gohrke, Volker J. Mobus, Rolf Kreienberg, Ingo Bernard Runnebaum;
Adenoviral transduction efficiency of ovarian cancer cells can be limited by loss of integrin beta3 subunit expression and increased by reconstitution of integrin alphaVbeta3.
Hum. Gene Ther. 12:391-399(2001) PubMed=15153938; DOI=10.1038/sj.cgt.7700727
Sven Roy Quist, Shan Wang-Gohrke, Tanja Kohler, Rolf Kreienberg, Ingo Bernard Runnebaum;
Cooperative effect of adenoviral p53 gene therapy and standard chemotherapy in ovarian cancer cells independent of the endogenous p53 status.
Cancer Gene Ther. 11:547-554(2004) |
|---|
| Cross-references |
|---|
| Encyclopedic resources |
Wikidata; Q54936866
|
|---|
| Entry history |
|---|
| Entry creation | 05-Sep-2014 |
|---|
| Last entry update | 19-Dec-2024 |
|---|
| Version number | 9 |
|---|
